ABO DIAG has been acquired by DIAGAST

The private shareholders and investment funds Succes Eur. and Aqui Invest, based in France, have sold ABO DIAG to DIAGAST for US$6.5 million.

ABO DIAG was founded in 2008 by its CEO, Najim Chaibi. Located in the technopolis of Montesquieu, the company is based on the research and development of diagnostic devices dedicated to blood transfusion and more widely to immuno-haematology. ABO DIAG is a pioneer in the field of research of new solutions for haematological diagnosis. The company's patent protected technology is based on immunological detection in vertical flow with colored dots. This innovation provides higher sensibility and higher safety in diagnosis, thanks to a simple user procedure and with standardized results. ABO DIAG was awarded the First Prize of Innovation at JIB 2012 (Innovation of the year in Biology).

DIAGAST is the worldwide leader in the marketing and development of reagents and instrumentation systems that aim to ensure donor and patient compatibility during blood transfusions. Over the last 30 years, the company has developed unparalleled expertise and know-how in the transfusion sector.

Oaklins' team in France advised the seller in this transaction.